The study of cSCC pathogenic mechanisms have recently identified potential pharmaceutical targets allowing the development of new systemic treatments, such as immunotherapy with immune checkpoint inhibitors [i.e., Cemiplimab, an anti-programmed cell death protein (PD)-1 antibody treatment] and epidermal growth factor receptor (EGFR) inhibitors. The gene discussed is EGFR; the disease is skin squamous cell carcinoma.